Globus Medical lowers 2026 revenue outlook to $3.09B while reiterating non-GAAP EPS of $4.95-$5.05 (NYSE:GMED)
Globus Medical (GMED) reported Q3 2026 revenue of $763.7M, down 0.7% YoY, citing impacts from Nevro rightsizing and delayed new products. The company lowered its 2026 revenue outlook to $3.09B but reiterated non-GAAP EPS guidance of $4.95-$5.05.
How this was made
The 30-second read
Why it matters
The guidance downgrade is likely to trigger a sell‑off, especially in the short term.
Market read
Guidance cuts are a primary catalyst for price movement; traders should consider short positions.
What to watch
Potential cost reductions or new product launches not reflected in the guidance.
Background
Globus Medical reported Q3 results and subsequently revised its full-year revenue guidance.
Ticker impact
Globus Medical lowered its 2026 revenue outlook to $3.09B, a fresh guidance downgrade.
downside pressure as investors price in the lower outlook
Guidance cuts are material and directly affect valuation expectations.
Market effects
May weigh on other medtech firms with similar product pipelines.
Limited to US and markets tracking medtech earnings.
Low; impact confined to the company and sector.
Counterpoint
If the revenue cut reflects temporary headwinds, the stock could rebound on later beat.
Key entities
- companyGlobus Medical
Medical device manufacturer (NYSE:GMED).
